A Phase 2 Randomized Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Previously Untreated Patients With Metastatic Triple-negative Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Tumor must be PD-L1- negative. 2) Adequate Laboratory measurements, blood counts – per protocol. 3) Measurable disease according to RECIST, version 1.1.

You may not be eligible for this study if the following are true:

  • 1) Active central nervous system (CNS) disease. 2) History of hemolytic anemia, autoimmune thrombocytopenia in the last 3 months. 3) Prior chemotherapy for metastatic disease.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.